NewLink Genetics: Rises on licensing deal for its cancer treatment

Lumos Pharma

24/12/2019 13:12

** Shares of drug developer  NLNK.O  rise ~13% to $2.2 in
premarket trade — among top pct. gainers across U.S. exchanges
    ** Company signed an exclusive worldwide license agreement
with Ellipses Pharma Ltd to develop and sell NLNK's cancer
treatment, NLG207  urn:newsml:reuters.com:*:nGNXbyBs2K
    ** The partnership will allow company to focus on its core
priorities - NLNK
    ** Up to Monday's close, stock had gained 28.3% this year

 (Reporting by Trisha Roy in Bengaluru)
 ((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6749 7786;))